Skip to content
OpenCapital
Get started

Pacira BioSciences, Inc. PCRX Gain on termination of lease

Gain on termination of lease at other companies

Avanos Medical logo
Avanos MedicalAVNS
$1.73M—

Other financials

Income statement

See full
Revenue$177.4M+5.0%
Gross profit$141.0M+4.7%
Operating income$6.9M+247%
Net income$2.9M-39.4%
EPS (diluted)$0.07-30.0%

Balance sheet

See full
Cash & equivalents$144.3M-49.1%
Total debt$411.2M+15.3%
Total equity$653.9M-18.1%
Total assets$1.2B-23.8%

Cash flow

See full
Operating cash flow$25.7M-27.6%
CapEx$2.7M-68.1%
Free cash flow$23.0M-14.7%

Valuation

See full
Market cap$942.78M-16.0%
Enterprise value$1.21B+1.2%
P/E183.5×—
P/S1.3×-0.3×

Profitability

See full
Gross margin79.3%+1.7pp
Operating margin3.3%—
Net margin0.7%—
FCF margin18.1%-4.6pp

Returns & leverage

See full
Return on equity0.7%—
Debt / equity0.6×+0.2×
Current ratio4.7×+2.3×

Where this comes from

Reported directly by Pacira BioSciences, Inc. in its filing.

Tagged under the XBRL concept us-gaap:GainLossOnTerminationOfLease.

The official record: Pacira BioSciences, Inc.’s 10-K, filed February 26, 2026, on SEC EDGAR. View the filing →

Ask your AI about Pacira BioSciences, Inc.'s gain on termination of lease.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Pacira BioSciences, Inc.'s gain on termination of lease?
Pacira BioSciences, Inc. (PCRX) reported gain on termination of lease of $0 in Q4 2025.
How has Pacira BioSciences, Inc.'s gain on termination of lease changed year-over-year?
Pacira BioSciences, Inc.'s gain on termination of lease increased by 100.0% year-over-year, from -$541.25K to $0.
What does gain on termination of lease mean?
Represents the non-cash gain or loss recognized upon the early termination of a lease agreement. This adjustment is necessary to reconcile net income with operating cash flow by removing the impact of accounting gains or losses that do not involve actual cash movement.